CN Mobile Logo


HER2-Positive Breast Cancer

ASCO 2016 Genitourinary Cancers Symposium

Cancer Network presents exclusive coverage from the American Society of Clinical Oncology (ASCO) 2016 Genitourinary Cancers Symposium, held January 7–9 in San Francisco. We’ll bring you reports as we cover the latest research, trials, scientific advances, and controversies that are changing the way genitourinary cancers are managed and treated.

HER2-Positive Breast Cancer

Patients diagnosed with HER2-amplified breast cancer at a younger age have a low risk of being a high-risk gene carrier, according to a new study examining susceptibility genes.

Two studies of the new HER2 selective tyrosine kinase inhibitor ONT-380 showed the drug has promising activity in HER2-positive breast cancer and especially in patients with central nervous system metastases.

T-DM1 improved survival in women with HER2-positive breast cancer, even after treatment with two or more other HER2-targeted therapies including trastuzumab and lapatinib.

Dual HER2 blockade with trastuzumab and lapatinib was no better than trastuzumab alone in producing pathologic complete responses in metastatic HER2-positive breast cancer patients in the neoadjuvant setting, according to a new study.

The use of afatinib failed to show a benefit in HER2-positive breast cancer patients with progressive brain metastases.

We acknowledge that the “more is better” approach may not always hold true. For example, preclinical data provided a rationale for combining pertuzumab with T-DM1, but recent reports suggest that this strategy may not prove more effective than single-agent T-DM1 therapy in the clinic.

The preferred status of CLEOPATRA-like regimens in the first-line HER2-positive metastatic breast cancer setting has recently been challenged by antibody-drug conjugate regimens based on ado-trastuzumab emtansine (T-DM1).


Subscribe to HER2-Positive Breast Cancer on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.